CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale SVP, Product Development & CTO sold 18,000 shares at $50.00 ($900,000)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $42.99 ($644,866)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $50.44 ($756,566)
- 4 Open-market sale SVP, General Counsel sold 5,000 shares at an average $53.23 ($266,161)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Scientific Officer sold 2,000 shares at an average $52.66 ($105,320)
- 4 Open-market sale Chief Financial Officer sold 10,000 shares at an average $60.75 ($607,539)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $58.53 ($877,989)
- 4 Exercise or conversion Chief Scientific Officer acquired 5,000 shares (option exercise)
- 4 Open-market sale Chief Financial Officer sold 3,068 shares at $60.01 ($184,111)
- 4 Open-market sale SVP, Product Development & CTO sold 5,300 shares at $54.05 ($286,465)
- 4 Open-market sale President and CEO sold 15,000 shares at an average $47.29 ($709,284)
Page 12 of 22 · 435 filings